1rarebird
04-26-2012, 02:08 PM
This abstract suggests good news for those who take tamoxifen and undergo chemo too.--bird
Oncologist. (http://www.ncbi.nlm.nih.gov/pubmed/22491005?dopt=Abstract#) 2012;17(4):499-507. Epub 2012 Apr 4.
Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy.
Romero WG (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Romero%20WG%22%5BAuthor%5D), Da Silva FB (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Da%20Silva%20FB%22%5BAuthor%5D), Borgo MV (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Borgo%20MV%22%5BAuthor%5D), Bissoli NS (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bissoli%20NS%22%5BAuthor%5D), Gouvêa SA (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gouv%C3%AAa%20SA%22%5BAuthor%5D), Abreu GR (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Abreu%20GR%22%5BAuthor%5D).
Source
Department Ciências Fisiológicas, Centro de Ciências da Saúde, UFES, Avenida Marechal Campos 1468, 29042-755 Vitória, ES, Brazil. grabreu@npd.ufes.br.
Abstract
Objectives. The objective of this study was to evaluate the effect of tamoxifen on blood markers that are associated with cardiovascular risk, such as C-reactive protein (CRP), apolipoprotein A-1 (Apo-A), and apolipoprotein B-100 (Apo-B), in women undergoing chemotherapy for breast cancer. Methods. Over a period of 12 months, we followed 60 women with breast cancer. The women were divided into the following groups: a group that received only chemotherapy (n = 23), a group that received chemotherapy plus tamoxifen (n = 21), and a group that received only tamoxifen (n = 16). Plasma CRP levels were assessed at 0, 3, 6, and 12 months, and Apo-A and Apo B levels as well as the Apo-B/Apo-A ratio were assessed at 0 and 12 months. Results. We found increases in the plasma concentration of CRP in the chemotherapy alone and chemotherapy plus tamoxifen groups after 3 and 6 months of treatment (before the introduction of tamoxifen). However, after 12 months of treatment, women who used tamoxifen (the chemotherapy plus tamoxifen and tamoxifen alone groups) showed a significant reduction in CRP and Apo-B levels and a decrease in the Apo-B/Apo-A ratio. A significant increase in serum Apo-A levels was observed in the group receiving chemotherapy alone as a treatment for breast cancer. Conclusion. The use of tamoxifen after chemotherapy for the treatment of breast cancer significantly reduces the levels of cardiovascular disease risk markers (CRP, Apo-B, and the Apo-B/Apo-A ratio).
PMID:22491005 [PubMed - in process
Oncologist. (http://www.ncbi.nlm.nih.gov/pubmed/22491005?dopt=Abstract#) 2012;17(4):499-507. Epub 2012 Apr 4.
Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy.
Romero WG (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Romero%20WG%22%5BAuthor%5D), Da Silva FB (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Da%20Silva%20FB%22%5BAuthor%5D), Borgo MV (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Borgo%20MV%22%5BAuthor%5D), Bissoli NS (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bissoli%20NS%22%5BAuthor%5D), Gouvêa SA (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gouv%C3%AAa%20SA%22%5BAuthor%5D), Abreu GR (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Abreu%20GR%22%5BAuthor%5D).
Source
Department Ciências Fisiológicas, Centro de Ciências da Saúde, UFES, Avenida Marechal Campos 1468, 29042-755 Vitória, ES, Brazil. grabreu@npd.ufes.br.
Abstract
Objectives. The objective of this study was to evaluate the effect of tamoxifen on blood markers that are associated with cardiovascular risk, such as C-reactive protein (CRP), apolipoprotein A-1 (Apo-A), and apolipoprotein B-100 (Apo-B), in women undergoing chemotherapy for breast cancer. Methods. Over a period of 12 months, we followed 60 women with breast cancer. The women were divided into the following groups: a group that received only chemotherapy (n = 23), a group that received chemotherapy plus tamoxifen (n = 21), and a group that received only tamoxifen (n = 16). Plasma CRP levels were assessed at 0, 3, 6, and 12 months, and Apo-A and Apo B levels as well as the Apo-B/Apo-A ratio were assessed at 0 and 12 months. Results. We found increases in the plasma concentration of CRP in the chemotherapy alone and chemotherapy plus tamoxifen groups after 3 and 6 months of treatment (before the introduction of tamoxifen). However, after 12 months of treatment, women who used tamoxifen (the chemotherapy plus tamoxifen and tamoxifen alone groups) showed a significant reduction in CRP and Apo-B levels and a decrease in the Apo-B/Apo-A ratio. A significant increase in serum Apo-A levels was observed in the group receiving chemotherapy alone as a treatment for breast cancer. Conclusion. The use of tamoxifen after chemotherapy for the treatment of breast cancer significantly reduces the levels of cardiovascular disease risk markers (CRP, Apo-B, and the Apo-B/Apo-A ratio).
PMID:22491005 [PubMed - in process